RxDoctor Payments Data

Krisczar Bungay, MD

Internal Medicine · New York, NYNPI 1942277660

Payments from drug & device makers

$554,185in general payments, 2019–2025

Across 1,962 payments — averaging $282.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$239K
  • Gilead$218K
  • Janssen Products, LP$34K
  • Idorsia Pharmaceuticals US Inc$18K
  • Merck$13K
  • AbbVie$5K
  • plus $27K from 54 others

What the payments were for

  • Consulting fees$52,6109%
  • Speaking & faculty fees$424,66777%
  • Travel & lodging$23,2514%
  • Food & beverage$53,26710%
  • Education$3900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company419$239,171
Gilead494$218,137
Janssen Products, LP60$34,496
Idorsia Pharmaceuticals US Inc65$17,809
Merck87$12,777
AbbVie(2 entities)175$5,042
Pfizer40$4,338
Eisai Inc.13$3,501
Lilly USA, LLC66$1,297
Shionogi Inc1$1,245
Novo Nordisk44$1,230
Biohaven Pharmaceuticals, Inc.2$1,221
Johnson & Johnson(2 entities)47$1,203
Axsome Therapeutics, Inc.21$1,045
AstraZeneca45$1,020
Amgen(2 entities)32$1,001
GSK30$852
Theratechnologies Inc.18$817
Boehringer Ingelheim26$764
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC33$706
Napo Pharmaceuticals Inc16$684
Supernus Pharmaceuticals, Inc.7$664
EMD Serono, Inc.29$648
Takeda Pharmaceuticals U.S.A., Inc.23$527
Lundbeck LLC22$474
Kowa Pharmaceuticals America, Inc.10$289
Astellas Pharma US Inc13$277
Bausch Health US, LLC12$248
Harmony Biosciences LLC7$246
Antares Pharma, Inc.11$216
Amarin Pharma, Inc.10$208
Otsuka America Pharmaceutical, Inc.9$207
Abbott1$161
Mylan Pharmaceuticals Inc.8$158
Jazz Pharmaceuticals Inc.6$132
Teva Pharmaceuticals USA, Inc.5$122
Globus Medical1$119
Aytu Biopharma, Inc.7$118
Exact Sciences4$109
Paratek Pharmaceuticals, Inc.5$100
Janssen Scientific Affairs, LLC1$96
Biohaven Pharmaceutical Holding Company Ltd.4$81
Adlon Therapeutics L.p.4$67
Mylan Institutional Inc.3$63
Biogen3$57
Phadia US Inc.3$55
Ironshore Pharmaceuticals Inc.2$44
VBI Vaccine (delaware) Inc.1$36
Ultragenyx Pharmaceutical Inc.2$36
Genentech USA, Inc.2$34
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$28
Hologic Sales And Service, LLC1$23
Alkermes, Inc.1$21
Halozyme Inc1$21
Circassia Inc.1$20
Corium, LLC1$20
Arbor Pharmaceuticals, Inc.1$18
Currax Pharmaceuticals LLC1$17
Acerus Pharmaceuticals Corporation1$17
Avion Pharmaceuticals1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$554,185 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$60,722
Medicare patients
250
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala446$1,909,851
DovatoDolutegravir Sodium/Lamivudine85$279,017
TivicayDolutegravir Sodium112$255,051
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$239,573
TriumeqAbacavir/Dolutegravir/Lamivudi62$232,461
PrezcobixDarunavir/Cobicistat78$182,890
OdefseyEmtricitab/Rilpiviri/Tenof Ala46$158,748
DescovyEmtricitabine/Tenofov Alafenam69$151,048
JulucaDolutegravir/Rilpivirine41$134,420
PifeltroDoravirine50$83,545
EliquisApixaban64$53,983
OzempicSemaglutide53$49,328
RybelsusSemaglutide31$42,847
JardianceEmpagliflozin36$38,434
IsentressRaltegravir Potassium17$38,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$218,137$2,060,899515 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca$239,171$900,948300 claims
Janssen Products, LPSymtuza$34,496$239,57347 claims
Johnson & JohnsonPrezcobix, Xarelto$1,203$203,08390 claims
MerckPifeltro, Isentress, Januvia$12,777$148,03789 claims
Novo NordiskOzempic, Rybelsus$1,230$92,17584 claims
PfizerEliquis, Effexor Xr$4,338$62,79079 claims
Boehringer IngelheimJardiance, Stiolto Respimat$764$43,43947 claims
Lilly USA, LLCMounjaro$1,297$37,99328 claims
GSKTrelegy Ellipta, Anoro Ellipta$852$28,51449 claims
Janssen Scientific Affairs, LLCEdurant$96$22,36312 claims
AstraZenecaFarxiga$1,020$10,99813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →